Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency

Venous Insufficiency Clinical Trial

Official title:

Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00835822
• Other study ID #: BRAZ-03-003
• Status: Completed
• Phase: Phase 4
• First received: February 2, 2009
• Last updated: February 3, 2009
• Start date: May 2005

Study information

• Verified date: February 2009
• Source: Abbott
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: Ethics CommitteeBrazil: National Health Surveillance Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the therapeutic efficacy and safety of Venocur Triplex®, administered BID for 60 days in patients with Chronic Venous Insufficiency rated between CEAP 2 and 4, in comparison to a Placebo group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 216
• Est. primary completion date: October 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The patient has confirmed his/her willingness to participate in the study, after being informed about all the aspects of the study that might be relevant for his/her decision to participate, and has signed and dated the informed consent form, as approved by the Institutional Review Board/ Ethics Committee (IRB/EC)

• Patients of both sexes, aged above 18 years and below 65 years

• Presence of uni- or bilateral varicose veins with CVI, in both sexes

• The patient's CVI is rated between functional classes CEAP 2 and 4

• Present at least one symptom of CVI prior to the study - leg pains, cramps, fatigue, heavy legs sensation.

Exclusion Criteria:

• If female, the patient has circulatory disorders exclusively during the pre-menstrual period

• If the patient is pregnant or breastfeeding

• The patient has received anticoagulants less than 15 days before study start

• The patient has used steroids or anti-inflammatory drugs less than 8 days before study start

• The patient has received radio or chemotherapy less than 7 days before study start

• The patient has used diuretics, phlebotrophic and venoactive drugs over the past 8 days before enrollment in the study

• The patient has used compression stockings less than 8 days before study start

• Trauma or surgical treatment over the past 30 days before study start

• Prior surgical treatment related to CVI (past 12 months for surgery and past 6 months for sclerotherapy)

• Immobilization of lower limbs over the past 6 months

• Known allergy to the product's ingredients

• Presence of chronic inflammatory diseases (rheumatoid arthritis, for instance), severe chronic infectious diseases (AIDS, tuberculosis, hanseniasis, etc.)

• The patient has suffered from phlebitis or deep venous thrombosis in the past 6 months before the study

• Fibrous lymphedema, primary or secondary lymphedema and lipoedema;

• Concomitant erysipelas

• Active fungal infections of the lower limbs

• Peripheral arteries disease, cerebrovascular or coronary disease

• Severe systemic conditions (heart failure, liver, pulmonary or kidney failure, active neoplastic disease, severe arterial hypertension, uncontrolled diabetes, among others), over the past 6 months before study start

• Hematocrit: < 32.0 mL RBC/dL for women and < 36.0 mL RBC/dL for men

• Hemoglobin: < 11.0 mL g/dL for women and < 12.0 mL g/dL for men;

• Total protein and fractions: Total protein < 6.4 g/dL, Albumin < 4.0 g/dL, Globulin < 1g/dL and Albumin/Globulin < 0.9%

• Serum creatinine: > 1.0 mg/dL for women and > 1.2 mg/dL for men or if patient in dialysis

• Aminotranferases (SGOT/AST and/or SGPT/ALT) more than twice the upper normal limit

• Participation in study with similar objectives over the past 6 months.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Venous Insufficiency

Intervention

Drug:
• Venocur Triplex®
Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
• placebo
Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Abbott	Statistika Consultoria Ltda

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of the score of the CVI symptoms, based on symptoms as leg pains, cramps, fatigue, aching legs, heavy legs sensation, heat or burning sensation and paresthesia (tingling/numbness)		60 days	No
Primary	Improvement of each CVI symptoms - leg pains, cramps, fatigue, aching legs, heavy legs sensation, heat or burning sensation and paresthesia (tingling/numbness);			No
Primary	Safety Assessment through the adverse events reports			Yes
Secondary	Reduction of edema in patients rated between CEAP 3 and 4, as compared to the Placebo group			No
Secondary	Effects of the study drug on the patient's quality of life using questionnaires SF-36 and CVIQ		60 days	No
Secondary	The global clinical improvement of the patient with CVI, using the CGI (Clinical Global Impression) scale.		60 days	No